Aptus Pharma Ltd

Aptus Pharma Ltd has announced a Board of Directors meeting scheduled for November 12, 2026. The primary agenda is to consider and approve the allotment of equity shares on a preferential basis. This allotment follows shareholder approval at the AGM on September 14, 2026, and in-principle approval from BSE on October 30, 2026. The allotment is contingent upon receiving subscription money and fulfilling all statutory and regulatory requirements.

Aptus Pharma Ltd has received in-principle approval from BSE Limited for a proposed preferential issue of equity shares. The approval, dated October 30, 2026, pertains to the issuance of 15,99,270 equity shares at a price not less than ₹280 per share to promoters and non-promoters. This follows shareholder approval at the Annual General Meeting held on September 14, 2026. BSE has advised the company to strengthen internal controls and obtain undertakings from allottees to prevent intra-day trading before allotment. The company must comply with all relevant SEBI regulations and ensure timely listing application post-allotment.

Aptus Pharma Ltd announced that its Board of Directors, in a meeting held on October 20, 2026, approved the unaudited standalone financial results for the half year ended September 30, 2026. The Statutory Auditors have issued a Limited Review Report on these results. Additionally, the company informed that the trading window for designated persons will open on October 23, 2026.

Aptus Pharma Ltd announced that its Board of Directors, in a meeting held on October 20, 2026, approved the unaudited financial results for the half-year ended September 30, 2026. The company also informed that the trading window for designated persons will reopen on October 23, 2026. The statutory auditors have issued a limited review report on the financial results.

Aptus Pharma Ltd has announced the closure of its trading window for dealing in the company's securities. This closure is in accordance with the company's Code of Conduct for Prohibition of Insider Trading. The trading window will be shut from October 01, 2026, and will reopen 48 hours after the declaration of the financial results for the half-year ended September 30, 2026. This measure is standard practice to prevent potential insider trading during periods of sensitive financial information disclosure.

Aptus Pharma Ltd has issued a corrigendum/addendum to its 16th Annual General Meeting (AGM) notice, originally scheduled for September 14, 2026. The correction pertains to inadvertent errors in the Explanatory Statement concerning Item No. 3, which relates to a proposed preferential issue of 16,02,870 Equity Shares. The company has provided the facility for remote e-voting through CDSL, with voting commencing on September 11, 2026, and concluding on September 13, 2026. The corrigendum was issued on September 7, 2026, and will be published in newspapers and uploaded to the company's website.

Aptus Pharma Limited is charting its next growth phase by focusing on developing its own manufacturing capabilities, strengthening its Pan-India presence, and exploring international markets. The company plans to raise ₹44.88 crore through a preferential issue of equity shares, subject to shareholder approval at the AGM on September 14, 2026. Funds will be allocated to capital expenditure (₹25 crore), working capital (₹10 crore), and general corporate purposes (₹9.88 crore). The long-term strategy includes meeting approximately 20% of product requirements through in-house manufacturing, expanding domestic sales and distribution, and exploring markets in Africa, the Middle East, and Latin America.

Aptus Pharma Ltd has submitted its Annual Report for the Financial Year 2025-26, which includes the Notice of the 16th Annual General Meeting (AGM). The AGM is scheduled to be held on September 14, 2026, at 11:00 AM IST, conducted via Video Conferencing (VC) / Other Audio-Visual Means (OAVM). The report, compliant with SEBI regulations, is also available on the company's website. It provides a comprehensive overview of the company's financial and operational performance, strategic priorities, and industry insights, while also including standard forward-looking statements and risk disclosures.

Aptus Pharma Ltd has announced its Annual General Meeting (AGM) will be held on Monday, September 14, 2026. The meeting will be conducted through Video Conferencing (VC) / Other Audio-Visual Means (OAVM). Key agenda items include the adoption of the Audited Financial Statements for the financial year ended March 31, 2026, the appointment of a director liable to retire by rotation, and the approval of a preferential allotment of equity shares. The company has also facilitated remote e-voting for its members through CDSL, with e-voting commencing on September 11, 2026, and concluding on September 13, 2026.

Aptus Pharma Ltd announced the outcome of its Board Meeting held on August 17, 2026. The board approved a preferential issue of 16,02,870 equity shares of face value ₹10 each at an issue price of ₹280 per share, aggregating to approximately ₹44.88 Crores. The meeting also took on record the valuation report, certificates from the Practicing Company Secretary and Statutory Auditor confirming compliance with SEBI ICDR Regulations and the Companies Act, 2013. Additionally, the board approved the convening of the 16th Annual General Meeting on September 14, 2026, to be held through Video Conferencing/Other Audio-Visual Means.